In the seven weeks since President Trump’s executive order on psychedelic therapies, the words “fast-tracked,” “breakthrough,” and “priority” have been used more or less interchangeably in coverage of the FDA’s response. They are not interchangeable. The agency runs five distinct acceleration programs, each created at different times under different legal authorities, each requiring different evidence, each producing different obligations.

The distinctions matter for two reasons. The first is reading the news accurately: a company that announces “FDA Breakthrough Therapy designation” has cleared a different bar than one that announces “Accelerated Approval,” and the press releases often obscure the difference. The second is reading sponsor signaling: a company that says it is “pursuing Accelerated Approval” is making a much more aggressive claim about its data than one that has received Breakthrough Therapy designation, and the gap between those two claims is where most of the FDA’s actual regulatory work happens.

This is a reference for what each program does and does not do. Use it when you read a press release that combines several of these terms in ways designed to sound more impressive than the underlying status warrants.

Fast Track designation

The oldest and least demanding of the five programs. Created under the Food and Drug Administration Modernization Act of 1997. Available to any drug intended to treat a serious condition with unmet medical need.

Fast Track designation can be requested very early in development, often based on preclinical and animal data alone. It does not require evidence in human patients. Receiving Fast Track means the FDA agrees the indication is serious and the proposed drug addresses an unmet need. That is a relatively low bar; many drugs in development meet it.

What Fast Track gets the sponsor: more frequent meetings with the FDA during development, rolling submission of sections of the eventual NDA (so the agency can begin review of completed sections before the full application is ready), and eligibility for Priority Review at the submission stage if other criteria are met.

What Fast Track does not get the sponsor: any change in the evidentiary standard for approval, any reduction in the studies required to support approval, or any guarantee of approval. Fast Track is a process accommodation, not a scientific judgment.

In coverage, “FDA grants Fast Track designation” is the weakest of the acceleration claims a company can make. It is meaningful, but the bar is low.

Breakthrough Therapy designation

Created by the FDA Safety and Innovation Act of 2012. The bar is meaningfully higher than Fast Track. Eligibility requires preliminary clinical evidence (evidence in human patients, not just animal data) suggesting the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint.

This is the designation most psychedelic programs have pursued, and most have received. MDMA received Breakthrough designation in August 2017. Compass’s psilocybin received it in October 2018. Usona’s psilocybin received it in 2019. Cybin’s CYB003 received it in March 2024.

What Breakthrough Therapy gets the sponsor: all the benefits of Fast Track, plus intensive guidance from FDA senior management on the design of the development program. The agency works closely with the sponsor on Phase 2 and Phase 3 design, often providing input on endpoints, statistical analysis plans, and the structure of the eventual NDA. Sponsors typically describe this engagement as the most valuable feature of the designation.

What Breakthrough Therapy does not get the sponsor: again, no change in the evidentiary standard for approval. A drug with Breakthrough Therapy designation must still demonstrate safety and effectiveness through adequate and well-controlled trials. The designation can be rescinded if subsequent data does not support the substantial-improvement finding, or if a competitor’s approval changes what constitutes “available therapy.” The Lykos MDMA program retained its Breakthrough Therapy designation through the August 2024 rejection; the designation did not prevent the CRL.

Roughly 29 percent of new drug approvals between 2003 and 2022 had received Breakthrough Therapy designation at some point in development. The designation is meaningful but, increasingly, common for drugs in serious indications.

Accelerated Approval

This is the program most often confused with the others, and the confusion matters most because Accelerated Approval is an approval pathway, not a designation. The previous four programs are designations granted during development; Accelerated Approval is a mechanism for actually approving the drug.

Created by FDA regulation in 1992 and codified in the FDA Modernization Act in 1997. Designed for drugs that treat serious conditions and fill an unmet medical need. The defining feature: Accelerated Approval allows the FDA to approve a drug based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than on a clinical endpoint directly measured.

This matters because surrogate endpoints can be measured faster than clinical endpoints. A drug for a slowly progressing disease that takes years to demonstrate clinical benefit can be approved on a surrogate marker (a biomarker, a radiographic finding, an intermediate clinical measure) that predicts the eventual clinical benefit. The most prominent recent example is the controversy around aducanumab and amyloid plaque reduction as a surrogate for clinical benefit in Alzheimer’s disease.

What Accelerated Approval gets the sponsor: actual marketing authorization for the drug, on the strength of surrogate-endpoint data, years before clinical-endpoint data would have been available.

What Accelerated Approval gets the sponsor at the cost of: a binding obligation to conduct confirmatory post-approval trials demonstrating the clinical benefit that the surrogate was predicting. If the confirmatory trials fail, the FDA can withdraw the approval. This has happened, though slowly and with substantial regulatory and political friction.

For psychedelic programs, Accelerated Approval is generally not available, because the indications (treatment-resistant depression, PTSD, major depressive disorder) do not have established surrogate endpoints that predict clinical benefit. The trials in these indications already measure the clinical endpoint directly. Sponsors who frame their programs as “pursuing Accelerated Approval” in indications where it is not structurally available are usually either confused about the program or signaling something other than what they appear to be signaling.

Priority Review

This is the simplest of the five. Created in 1992. It is a designation granted at the time of NDA submission, not during development. Priority Review shortens the FDA’s review clock from the standard 10 months to 6 months.

A drug qualifies for Priority Review if it would, if approved, provide significant improvement in safety or effectiveness in the treatment, diagnosis, or prevention of a serious condition. Drugs with Breakthrough Therapy designation automatically qualify; other drugs can request it separately.

Priority Review does not change anything about the evidentiary standard or the studies required. It changes only the speed of the agency’s review after submission. For a company with a fully prepared NDA, Priority Review is meaningful in shaving four months off the path to a launch decision.

In coverage, “FDA grants Priority Review” is genuinely meaningful but narrow. It compresses the review window. It does not predict the review outcome.

Commissioner’s National Priority Voucher

The newest program. Established as an FDA pilot program announced in June 2025, expanded to psychedelics by President Trump’s executive order of April 18, 2026, and first awarded to psychedelic programs on April 24, 2026, when vouchers went to Compass Pathways, the Usona Institute, and Transcend Therapeutics (now being acquired by Otsuka).

The voucher compresses review further than Priority Review does, to a one-to-two-month window after NDA submission. It also includes enhanced communications with the FDA during the lead-up to filing. Sponsors describe it as the most aggressive acceleration program the agency has offered.

Eligibility requires Breakthrough Therapy designation and that the program meet additional criteria of the Commissioner’s program, which leave substantial discretion to the FDA commissioner. The criteria are not entirely transparent. A program with Breakthrough Therapy designation is eligible to be considered; it is not entitled to a voucher. The April 24 selections of Compass, Usona, and Transcend over Resilient Pharmaceuticals (which also held Breakthrough Therapy designation for its MDMA program) demonstrated this. Resilient was eligible. The agency chose otherwise.

The voucher is a designation, not an approval pathway. It does not change the evidentiary standard. Every voucher recipient explicitly noted this in its public statements. Compass framed it as “process efficiencies.” Usona stated that the voucher “does not alter scientific or regulatory standards.”

How they stack

For a sponsor’s purposes, the five programs are not alternatives; they are stages of a pipeline.

A program in early development with preclinical data might receive Fast Track designation. As Phase 2 data accumulates and shows substantial improvement over available therapy, the program might receive Breakthrough Therapy designation in addition to Fast Track. When the NDA is filed, the program receives Priority Review automatically by virtue of holding Breakthrough Therapy. If the program is also selected for a Commissioner’s National Priority Voucher, the review window compresses further to one or two months. None of these acceleration mechanisms is mutually exclusive.

Accelerated Approval is the separate question. It applies only at the time of approval, only for drugs in indications with appropriate surrogate endpoints, and it creates post-approval obligations the other programs do not.

What none of them do

The shared feature of all five programs, the one that is often lost in coverage, is that none of them reduces the evidentiary standard for approval. They accelerate communication, shorten review timelines, and in the case of Accelerated Approval allow surrogate endpoints, but they all require the same fundamental demonstration of safety and effectiveness through adequate and well-controlled trials.

This is why the Lykos MDMA program was rejected despite holding Breakthrough Therapy designation, Special Protocol Assessment, and the active engagement of FDA senior management throughout its development. The accelerations were real, the engagement was real, and the application was still rejected on the data.

This is also why the Compass Pathways program, with all the same designations now stacked, is not guaranteed to succeed. The voucher compresses review. The data still has to support approval. The methylone program, the third voucher recipient, is only entering Phase 3 and is years from filing an NDA. The voucher signals priority; it does not signal approval.

The clearest summary: designations and review mechanisms are about speed and engagement. They are not about the standard. The standard sits where it has always sat. Programs that meet it get approved, whatever combination of accelerations they have stacked. Programs that do not meet it get rejected, whatever combination of accelerations they have stacked.

Read every press release in that frame, and most of the confusion in the psychedelic regulatory conversation resolves.